Cross-reactive dengue human monoclonal antibody prevents severe pathologies and death from Zika virus infections
Yiu-Wing Kam, … , Lisa F.P. Ng, Laurent Rénia
Yiu-Wing Kam, … , Lisa F.P. Ng, Laurent Rénia
Published April 20, 2017
Citation Information: JCI Insight. 2017;2(8):e92428. https://doi.org/10.1172/jci.insight.92428.
View: Text | PDF
Research Article Infectious disease

Cross-reactive dengue human monoclonal antibody prevents severe pathologies and death from Zika virus infections

Abstract

Zika virus (ZIKV) infections have been linked with neurological complications and congenital Zika syndrome. Given the high level of homology between ZIKV and the related flavivirus dengue virus (DENV), we investigated the level of cross-reactivity with ZIKV using a panel of DENV human mAbs. A majority of the mAbs showed binding to ZIKV virions, with several exhibiting neutralizing capacities against ZIKV in vitro. Three of the best ZIKV-neutralizing mAbs were found to recognize diverse epitopes on the envelope (E) glycoprotein: the highly conserved fusion-loop peptide, a conformation-specific epitope on the E monomer, and a quaternary epitope on the virion surface. The most potent ZIKV-neutralizing mAb (SIgN-3C) was assessed in 2 type I interferon receptor–deficient (IFNAR–/–) mouse models of ZIKV infection. Treatment of adult nonpregnant mice with SIgN-3C rescued mice from virus-induced weight loss and mortality. The SIgN-3C variant with Leu-to-Ala mutations in the Fc region (SIgN-3C-LALA) did not induce antibody-dependent enhancement (ADE) in vitro but provided similar levels of protection in vivo. In pregnant ZIKV-infected IFNAR–/– mice, treatment with SIgN-3C or SIgN-3C-LALA significantly reduced viral load in the fetal organs and placenta and abrogated virus-induced fetal growth retardation. Therefore, SIgN-3C-LALA holds promise as a ZIKV prophylactic and therapeutic agent.

Authors

Yiu-Wing Kam, Cheryl Yi-Pin Lee, Teck-Hui Teo, Shanshan W. Howland, Siti Naqiah Amrun, Fok-Moon Lum, Peter See, Nicholas Qing-Rong Kng, Roland G. Huber, Mei-Hui Xu, Heng-Liang Tan, Andre Choo, Sebastian Maurer-Stroh, Florent Ginhoux, Katja Fink, Cheng-I Wang, Lisa F.P. Ng, Laurent Rénia

×

Figure 1

Binding and neutralizing activity of human DENV mAbs against Zika virus.

Options: View larger image (or click on image) Download as PowerPoint
Binding and neutralizing activity of human DENV mAbs against Zika virus....
(A) Level of recognition of Zika virus (ZIKV) whole virions by human dengue virus (DENV) mAbs was tested at 1 μg/ml (n = 3) and determined by ELISA using purified ZIKV virions. Data are presented as mean ± SD. (B–D) Neutralizing capacities of selected human DENV mAbs against ZIKV in vitro. ZIKV was preincubated with serial dilutions of human DENV mAbs 1B-H1L1 (B), 2F-H1L3 (C), or SIgN-3C (D) prior to infecting Vero-E6 cells at MOI of 10. Mock-infected and virus-only conditions were used as controls. Infectivity was quantified 48 hours after infection by immunofluorescence. Data are presented as mean ± SEM of 3 to 4 independent experiments, normalized to virus-only control. Nonlinear regression fitting was used to determine the IC50 values. (E) Binding curves of selected mAbs by ZIKV virion ELISA. OD values were normalized to the result at 30 μg/ml mAb.